Related Experiment Videos
Medroxyprogesterone acetate does not induce antipyrine clearance and only weakly increases alpha 1-acid glycoprotein
Abstract:
The synthetic progestin medroxyprogesterone acetate (MPA) has previously been shown to be an inducer of hepatic microsomal cytochrome P-450 in both man and the rat. We have assessed the ability of a variety of oral doses of MPA to induce either hepatic cytochrome P-450 as measured by antipyrine clearance or alpha 1-acid glycoprotein (AGP) in beagle dogs. Over the range of 25 mg/d to 400 mg/d, MPA did not induce antipyrine clearance. The concentration of AGP only increased at the 400 mg/d level, and was effected to a much smaller extent than has been previously observed for other inducing agents. MPA was also tested as a promoter of induction by combining it with a course of rifampin capable of substantially elevating both antipyrine clearance and AGP. MPA was without effect. The results of these experiments are discussed in light of the toxicology of MPA in beagles.
Insights
Medroxyprogesterone acetate (MPA) did not significantly induce liver enzymes like cytochrome P-450 or alpha 1-acid glycoprotein (AGP) in beagle dogs, even at high doses. MPA also failed to enhance induction when combined with rifampin.
Area of Science:
- Pharmacology
- Toxicology
- Biochemistry
Background:
- Medroxyprogesterone acetate (MPA), a synthetic progestin, is known to induce hepatic microsomal cytochrome P-450 in humans and rats.
- Understanding drug-metabolizing enzyme induction is crucial for predicting drug-drug interactions and toxicity.
Purpose of the Study:
- To evaluate the potential of medroxyprogesterone acetate (MPA) to induce hepatic cytochrome P-450 and alpha 1-acid glycoprotein (AGP) in beagle dogs.
- To assess if MPA can act as a co-inducer of these enzymes when administered with rifampin.
Main Methods:
- Beagle dogs were administered various oral doses of MPA (25-400 mg/d).
- Hepatic cytochrome P-450 induction was assessed by measuring antipyrine clearance.
- Alpha 1-acid glycoprotein (AGP) levels were quantified.
- MPA was tested in combination with rifampin to evaluate its potential as an induction promoter.
Main Results:
- MPA did not induce antipyrine clearance across the tested dose range (25-400 mg/d).
- AGP levels showed a minor increase only at the highest MPA dose (400 mg/d), significantly less than with other known inducers.
- MPA did not enhance the induction of antipyrine clearance or AGP when co-administered with rifampin.
Conclusions:
- Medroxyprogesterone acetate (MPA) exhibits minimal to no induction potential for hepatic cytochrome P-450 and AGP in beagle dogs.
- MPA does not appear to act as a significant promoter of enzyme induction in this species.
- These findings contribute to the toxicological profile of MPA in beagles.